Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: Study based on an enzyme-linked assay and immunohistochemical staining

被引:21
|
作者
Endo T. [1 ]
Nakabayashi K. [1 ]
Sekiuchi M. [1 ]
Kuroda T. [1 ]
Soejima A. [1 ]
Yamada A. [1 ]
机构
[1] First Department of Internal Medicine, Kyorin University, School of Medicine, Mitaka, Tokyo 181-8611
关键词
Glomerulonephritis; Metalloproteinase; Tissue inhibitor of metalloproteinase;
D O I
10.1007/s10157-006-0438-3
中图分类号
学科分类号
摘要
Background. Various glomerular diseases progress to end-stage renal failure due to an accumulation of the mesangial matrix (MM) and a thickening of the glomerular basement membrane (GBM). Both the MM and GBM are consistently metabolized through the synthesis and destruction of the matrix. Such synthesis is influenced by transforming growth factor-β (TGF-β) and other factors, whereas the destruction is presumed to be mediated by both matrix metalloproteinases (MMPs) and inhibitors of matrix metalloproteinases (TIMPs). Based on such evidence, we tried to detect MMP-2, MMP-9, and TIMP-1 in the peripheral blood of patients with various glomerular diseases. Methods. Serum was used to detect MMP-2 and TIMP-1, while plasma was used to detect MMP-9. These enzymes were detected using an enzyme-linked assay. Results. The findings showed an increased level of MMP-2 in patients with a alteration of GBM, typically membranous nephropathy (MN), regardless of the differences in their etiological processes. In contrast, MMP-9 did not show a strong association with any specific glomerular abnormalities. However, it mainly tended to increase in patients with MM accumulation. In addition, the localization of MMP-2, MMP-9, and TGF-β1 was studied using immunohistochemical staining. MMP-2 was demonstrated to exist in the glomerular capillary loop (GCL) as well as in the mesangial cells and the mesangial matrix. MMP-9 was found to exist in mesangial cells and the matrix, GCL, infiltrated neutrophils, and some tubular epithelial cells. Positive staining for TGF-β1 in GCL was found to be associated with an increased level of MMP-2 in patients with MN, whereas in MM such positive staining was not necessarily associated with an increased level of MMP-9. Conclusions. These results therefore suggest that MMP-2 plays an important role in the degradation of GBM, while MMP-9 only moderately affects the degradation of MM. © 2006 Japanese Society of Nephrology.
引用
收藏
页码:253 / 261
页数:8
相关论文
共 50 条
  • [31] Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge
    Cataldo, DD
    Bettiol, J
    Noël, A
    Bartsch, P
    Foidart, JM
    Louis, R
    CHEST, 2002, 122 (05) : 1553 - 1559
  • [32] Matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase2 and-9 and tissue inhibitor of metalloproteinase-1 during human dermal wound healing
    Gillard, JA
    Reed, MWR
    Buttle, D
    Cross, SS
    Brown, NJ
    WOUND REPAIR AND REGENERATION, 2004, 12 (03) : 295 - 304
  • [33] Expression of matrix metalloproteinase-2 and-9 and of tissue inhibitor of matrix metalloproteinase-1 in liver regeneration from oval cells in rat
    Van, T. Pham
    Couchie, D.
    Martin-Garcia, N.
    Laperche, Y.
    Zafrani, E. S.
    Mavier, P.
    MATRIX BIOLOGY, 2008, 27 (08) : 674 - 681
  • [34] Study of the level of sputum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor metalloproteinase-1 (TIMP-1) in COPD patients
    Esa, Sherif A.
    Rawy, Abeer M.
    El-Behissy, Mona M.
    Kamel, Mohamed H.
    El-Hwaitty, Hany Mohiy Mohamed Mustafa
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2014, 63 (04): : 870 - 876
  • [35] Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension - Relationship to tissue doppler indices of diastolic relaxation
    Tayebjee, MH
    Nadar, SK
    MacFadyen, RJ
    Lip, GYH
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (09) : 770 - 774
  • [36] Circulating β-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients -: Role of oxidative stress
    Pawlak, K
    Pawlak, D
    Mysliwiec, M
    CYTOKINE, 2005, 31 (01) : 18 - 24
  • [37] Association of Body Mass Index with Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Interleukin-6 Based on Blood Pressure
    Samara, Tjam Diana
    Wartono, Magdalena
    Kosasih, Adrianus
    Alvina, Alvina
    REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2024, 13 (01): : 137 - 143
  • [38] Serum Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1 and Matrix Metalloproteinase-9/Neutrophil Gelatinase-associated Lipocalin Complex Levels in Patients with Early-stage Diabetic Nephropathy
    Cakirca, Gokhan
    Turgut, Faruk Hilmi
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2018, 12 (05) : 299 - 304
  • [39] Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer
    I. Kirman
    S. Jain
    V. Cekic
    A. Belizon
    E. Balik
    P. Sylla
    T. Arnell
    K. A. Forde
    R. L. Whelan
    Surgical Endoscopy And Other Interventional Techniques, 2006, 20 : 706 - 706
  • [40] Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) as blood biomarkers of Alzheimer's disease
    Basic, J.
    Milosevic, V.
    Djordjevic, B.
    Stojiljkovic, V.
    Malobabic, M.
    Stoimenov, T. Jevtovic
    Stojanovic, I.
    FEBS OPEN BIO, 2022, 12 : 125 - 126